Schrödinger has announced a strategic collaboration and software agreement with Bristol Myers Squibb to deploy its AI Co-Scientist platform, Bunsen, for drug discovery applications. The partnership aims to leverage Bunsen’s agentic AI capabilities to accelerate the drug discovery process. Financial and additional implementation details of the agreement were not disclosed in the announcement.